Premium
P4‐047: EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE WITH THE β‐AMYLOID 42/40 CSF CONCENTRATION RATIO: ANALYTICAL AND CLINICAL VALIDATION OF TWO NOVEL ASSAYS
Author(s) -
Lewczuk Piotr,
Lelental Natalia,
Maler Juan Manuel,
Spitzer Philipp,
Kornhuber Johannes
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1561
Subject(s) - repeatability , cerebrospinal fluid , amyloid β , dementia , diagnostic accuracy , neurochemical , medicine , alzheimer's disease , disease , pathology , chromatography , chemistry
Conclusions (1) In this study, the analytical validation of the novel Aß1-40 and Aß1-42 ELISA assays (IBL International GmbH, Hamburg, Germany) taking into consideration their specificities, linearity, precision, repeatability of the standard curves, recovery, etc., showed that the novel IBL International Aß1-40 and Aß1-42 ELISA assays characterize with excellent analytical performance; (2)Moreover, the simultaneous measurement of the two Aß isoforms by splitting one diluted CSF sample and using the same protocol for both assays means a huge improvement over other currently available assays for establishing the Aß42/40 ratio; and (3) A clinical study in order to test the hypothesis of better CSF Aß42/40 diagnostic performance compared to the CSF Aß42 concentration alone reconfirmed that the CSF Aß42/40 concentration ratio shows significantly better diagnostic performance compared to measuring the CSF Aß42 concentration alone.